JP6067203B2 - ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 - Google Patents

２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 Download PDF

Info

Publication number
JP6067203B2
JP6067203B2 JP2009536219A JP2009536219A JP6067203B2 JP 6067203 B2 JP6067203 B2 JP 6067203B2 JP 2009536219 A JP2009536219 A JP 2009536219A JP 2009536219 A JP2009536219 A JP 2009536219A JP 6067203 B2 JP6067203 B2 JP 6067203B2
Authority
JP
Japan
Prior art keywords
balsalazide
food
composition
administration
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009536219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509326A5 (https=
JP2010509326A (ja
Inventor
ローリン ジョンソン，
ローリン ジョンソン，
Original Assignee
サリックス ファーマシューティカルズ， インコーポレイテッド
サリックス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サリックス ファーマシューティカルズ， インコーポレイテッド, サリックス ファーマシューティカルズ， インコーポレイテッド filed Critical サリックス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2010509326A publication Critical patent/JP2010509326A/ja
Publication of JP2010509326A5 publication Critical patent/JP2010509326A5/ja
Application granted granted Critical
Publication of JP6067203B2 publication Critical patent/JP6067203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2009536219A 2006-11-03 2007-03-23 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 Expired - Fee Related JP6067203B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/592,854 US8921344B2 (en) 2006-11-03 2006-11-03 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US11/592,854 2006-11-03
PCT/US2007/007438 WO2008063211A2 (en) 2006-11-03 2007-03-23 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012248573A Division JP2013032395A (ja) 2006-11-03 2012-11-12 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用

Publications (3)

Publication Number Publication Date
JP2010509326A JP2010509326A (ja) 2010-03-25
JP2010509326A5 JP2010509326A5 (https=) 2011-03-03
JP6067203B2 true JP6067203B2 (ja) 2017-01-25

Family

ID=38263983

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009536219A Expired - Fee Related JP6067203B2 (ja) 2006-11-03 2007-03-23 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用
JP2012248573A Pending JP2013032395A (ja) 2006-11-03 2012-11-12 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012248573A Pending JP2013032395A (ja) 2006-11-03 2012-11-12 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用

Country Status (12)

Country Link
US (1) US8921344B2 (https=)
EP (1) EP2096912B1 (https=)
JP (2) JP6067203B2 (https=)
KR (2) KR20090118906A (https=)
CN (1) CN101610670A (https=)
AU (1) AU2007322362B2 (https=)
BR (1) BRPI0717859A2 (https=)
CA (2) CA3004028C (https=)
DK (1) DK2096912T3 (https=)
IL (1) IL198513B (https=)
MX (1) MX2009004826A (https=)
WO (1) WO2008063211A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
CA2555304C (en) 2004-02-06 2016-06-28 Nicolas Peter Shortis Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
ITMI20071965A1 (it) * 2007-10-11 2009-04-12 Domenico Russo Composizione farmaceutica comprendente sucralfato e mesalazina
CN102238868A (zh) * 2008-10-03 2011-11-09 福尔克博士药物有限责任公司 使用颗粒状5-氨基水杨酸治疗肠病的组合物和方法
WO2010077911A1 (en) * 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Enema formulations
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2563117B1 (en) * 2010-04-26 2018-02-21 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
SMT202500474T1 (it) * 2010-12-03 2026-01-12 Nalpropion Pharmaceuticals Llc Aumento della biodisponibilità farmacologica nella terapia con naltrexone
CN103483220B (zh) * 2013-06-09 2015-06-17 陕西新药技术开发中心 一种化合物及其制备方法和抗溃疡性结肠炎用途
CN103333084B (zh) * 2013-06-09 2015-01-07 陕西新药技术开发中心 3,3’-偶氮双[6-(丁酰氧基)苯甲酸]及其制备方法和应用
CN104706582A (zh) * 2013-12-12 2015-06-17 四川健能制药有限公司 含有美沙拉秦的药物组合物
US10100005B1 (en) * 2017-11-17 2018-10-16 Eclipse Therapeutics, LLC Mesalazine derivatives
JP2020090456A (ja) * 2018-12-05 2020-06-11 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791889A (fr) 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4960765A (en) 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS57500432A (https=) 1980-03-20 1982-03-11
EP0039306B1 (de) 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
US4412922A (en) 1980-07-02 1983-11-01 Abcor, Inc. Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4562024A (en) 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
SE8405924L (sv) 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5374430A (en) 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
JP2733849B2 (ja) 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法
US5064637A (en) 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
US5095073A (en) 1990-03-02 1992-03-10 Exxon Research And Engineering Company Water soluble rigid rod sulfonated aromatic polyamide
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
DE59307753D1 (de) 1992-03-11 1998-01-15 Asta Medica Ag Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
JPH08169847A (ja) 1994-12-16 1996-07-02 Morishita Roussel Kk 固形製剤
US5905073A (en) 1995-01-06 1999-05-18 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (sv) 1997-03-14 1997-03-14 Astra Ab New formulation
AR012304A1 (es) 1997-04-01 2000-10-18 Borody Thomas J Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US20030078205A1 (en) 2001-07-31 2003-04-24 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6144381A (en) 1997-05-14 2000-11-07 International Business Machines Corporation Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US5927500A (en) 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
KR100634953B1 (ko) 1998-07-20 2006-10-17 스미스클라인 비참 코포레이션 에프로사르탄을 포함하는 생물학적으로 강화된 경구 고형투여 형태의 제제
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20030138399A1 (en) 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
AU2001285489A1 (en) 2000-08-29 2002-03-13 Nobex Corporation 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US6562871B1 (en) 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US20030190352A1 (en) 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
CA2555304C (en) 2004-02-06 2016-06-28 Nicolas Peter Shortis Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2007025146A2 (en) 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
WO2008033125A1 (en) 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate

Also Published As

Publication number Publication date
EP2096912A2 (en) 2009-09-09
IL198513A0 (en) 2010-02-17
CN101610670A (zh) 2009-12-23
AU2007322362A1 (en) 2008-05-29
DK2096912T3 (en) 2018-08-27
US20070167416A1 (en) 2007-07-19
BRPI0717859A2 (pt) 2013-01-22
IL198513B (en) 2018-05-31
CA3004028C (en) 2021-07-13
CA2668441A1 (en) 2008-05-29
CA3004028A1 (en) 2008-05-29
JP2010509326A (ja) 2010-03-25
KR20090118906A (ko) 2009-11-18
WO2008063211A3 (en) 2008-11-20
EP2096912B1 (en) 2018-05-30
CA2668441C (en) 2018-06-12
JP2013032395A (ja) 2013-02-14
AU2007322362B2 (en) 2013-06-20
EP2096912A4 (en) 2010-01-06
MX2009004826A (es) 2009-07-17
KR20140098863A (ko) 2014-08-08
US8921344B2 (en) 2014-12-30
WO2008063211A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
JP6067203B2 (ja) ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用
US7625884B2 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP5993074B2 (ja) 放射線直腸ｓ状結腸炎を処置するための組成物および方法
CN101534840A (zh) 治疗放射性肠炎的方法
AU2013228061B2 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP2013525440A (ja) 男性の治療のための２−ヒドロキシ−５−フェニルアゾ安息香酸誘導体の製剤および使用
HK1134221B (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
HK1134221A (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN121197128A (zh) 对乙酰氨基酚与非那西丁的组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140526

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150318

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150501

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161221

R150 Certificate of patent or registration of utility model

Ref document number: 6067203

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees